Metagenomi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Metagenomi Therapeutics

07/08/2026 12:26

Metagenomi Therapeutics Inc MGX.OQ MGX.O is expected to  show a fall in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Emeryville California-based  company is expected to report a 65.2% decrease in revenue to $2.96 million from $8.51 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Metagenomi Therapeutics Inc is for a loss of 57 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Metagenomi Therapeutics Inc is $9.00, about 625.8% above its last closing price of $1.24
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.52
-0.53
-0.61
Missed
-15.8
Dec. 31 2026
-0.59
-0.61
-0.60
Beat
0.9
Sep. 30 2025
-0.55
-0.58
-0.55
Beat
5.8​
Jun. 30 2025
-0.62
-0.62
-0.54
Beat
13
​​Mar. 31 2025
-0.50
-0.58
-0.68
Missed
-17.6
Dec. 31 2024
-0.66
-0.75
-0.63
Beat
16​
Sep. 30 2024
-0.77
-0.78
-0.51
Beat
34.3
Jun. 30 2024
-0.62
-0.65
-0.29
Beat
55.6
This summary was machine generated August 7 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)